RxDoctor Payments Data

Sanaullah Khalid, MD

Hematology & Oncology · Youngstown, OHNPI 1811285562

Payments from drug & device makers

$266,506in general payments, 2019–2025

Across 837 payments — averaging $318.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$171K
  • Jazz Pharmaceuticals Inc.$47K
  • Merck$10K
  • Verastem, Inc.$8K
  • GSK$8K
  • Sun Pharmaceutical Industries Inc.$6K
  • plus $17K from 54 others

What the payments were for

  • Consulting fees$30,69512%
  • Speaking & faculty fees$210,57879%
  • Travel & lodging$7,9223%
  • Food & beverage$16,7446%
  • Education$5670%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
E.r. Squibb & Sons, L.L.C.150$170,848
Jazz Pharmaceuticals Inc.46$47,433
Merck55$9,509
Verastem, Inc.1$7,920
GSK17$7,621
Sun Pharmaceutical Industries Inc.6$5,504
AstraZeneca(2 entities)48$3,250
Sirtex Medical Inc2$2,695
Bristol Myers Squibb25$1,137
Novartis56$996
Pfizer59$899
EMD Serono, Inc.11$758
Beigene USA, Inc.3$578
Takeda Pharmaceuticals U.S.A., Inc.25$551
Sanofi24$468
Johnson & Johnson23$426
AbbVie16$382
Astellas Pharma US Inc14$346
ASD Specialty Healthcare, LLC5$290
Daiichi Sankyo Inc.13$278
Eisai Inc.14$272
Amgen14$257
Lilly USA, LLC14$253
Genentech USA, Inc.12$244
Exelixis Inc.12$231
Pharmacyclics LLC, An Abbvie Company11$221
Acrotech Biopharma Inc.10$201
Incyte Corporation11$199
Bayer9$166
Ipsen Biopharmaceuticals, Inc9$165
Array Biopharma Inc9$157
AVEO Pharmaceuticals, Inc.6$146
Regeneron Healthcare Solutions, Inc.5$130
Seagen Inc.6$107
Genmab U.S., Inc.5$104
Stemline Therapeutics Inc.5$101
Rigel Pharmaceuticals, Inc.5$95
Gilead4$93
Myovant Sciences Inc.4$92
ADC Therapeutics America, Inc.4$91
Kyowa Kirin, Inc.6$89
Beone Medicines USA, Inc.3$78
Sumitomo Pharma America, Inc.3$78
Blueprint Medicines Corporation4$77
Boehringer Ingelheim4$74
Karyopharm Therapeutics Inc.4$71
Heron Therapeutics, Inc.3$61
Tesaro, Inc.3$58
Caris MPI, Inc.2$50
Pharmacosmos Therapeutics Inc.3$48
Dendreon Pharmaceuticals LLC2$41
Sobi, Inc2$40
Emmaus Medical, Inc.2$40
Tolmar, Inc.2$38
Puma Biotechnology, Inc.2$37
Morphosys, US Inc.2$33
Tolmar Pharmaceuticals, Inc.2$33
Dova Pharmaceuticals2$30
Taiho Oncology, Inc.2$29
Fennec Pharmaceuticals, Inc.1$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$266,506 in reported general payments places this provider in the 75th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$5,236,961
Medicare patients
477
Services billed
301,186

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib91$1,448,533
Darzalex FasproDaratumumab-Hyaluronidase-Fihj141$1,344,953
XtandiEnzalutamide63$834,594
PomalystPomalidomide33$623,709
CabometyxCabozantinib S-Malate24$594,167
Lenalidomide64$584,651
OctagamImmun Globg(Igg)/Malt/Iga Ov5088$459,715
RevlimidLenalidomide39$458,648
BrukinsaZanubrutinib31$432,164
ReblozylLuspatercept-Aamt17$351,136
Neulasta OnproPegfilgrastim54$330,787
SprycelDasatinib16$311,370
OrgovyxRelugolix116$305,654
LenvimaLenvatinib Mesylate12$293,250
KisqaliRibociclib Succinate16$266,897

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmacyclics LLC, An Abbvie CompanyImbruvica$221$1,448,53391 claims
E.r. Squibb & Sons, L.L.C.Pomalyst, Reblozyl, Sprycel$170,848$1,286,21566 claims
Astellas Pharma US IncXtandi$346$834,59463 claims
Exelixis Inc.Cabometyx$231$594,16724 claims
PfizerOctagam, Eliquis, Retacrit$899$504,756163 claims
Bristol Myers SquibbRevlimid$1,137$458,64839 claims
Beigene USA, Inc.Brukinsa$578$432,16431 claims
AstraZenecaTagrisso, Calquence$3,250$352,69923 claims
NovartisKisqali, Sandostatin Lar Depot$996$351,20231 claims
Sumitomo Pharma America, Inc.Orgovyx$78$305,654116 claims
Eisai Inc.Lenvima$272$293,25012 claims
AmgenXgeva, Aranesp$257$293,064146 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Youngstown

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →